Close
Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1

Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme.

Some people with ALS, the most common form of MND, also develop a form of dementia known as frontotemporal dementia (FTD). FTD is a group of disorders where the nerve cells in two sets of lobes (frontal and temporal) in the brain are damaged. In a similar way to how motor neurones break down in MND and cause loss of function in muscles, the damage to the nerve cells in FTD causes the connections between parts of the brain to break down. As more cells become damaged and die this can lead to symptoms such as problems with memory, thinking or language, changes in mood, emotions and behaviour.

Behind the headlines: could a potential treatment for MND be developed into a nasal spray?

Behind the headlines: could a potential treatment for MND be developed into a nasal spray?

Reading Time: 6 minutes Recent research, led by Professor Guillaume Hautbergue at the University of Sheffield, has found a potential new method of preventing nerve cell death in the most common genetic form of MND. This new method could, with further studies, lead to the development of a potential therapy for C9orf72 MND, and a type of dementia called…

Assessing cognitive change

Assessing cognitive change

Reading Time: 5 minutes This is blog number 8 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page might take a minute to load). Up to half of…

Exploring the interaction between TDP-43 and RNA

Reading Time: 3 minutes In light of the upcoming Biomedical Research Advisory Panel meeting happening on Friday 7 April that will discuss which new research projects the MND Association will fund, we are pleased to report on the progress of one of our already-funded researchers. In their three year project, funded by the MND Association, Prof Annalisa Pastore (King’s College London)…